CST, 33052SF, PD-L1 (Atezolizumab Biosimilar) Human Monoclonal Antibody

Monoclonal Antibody for studying PD-L1. Validated for Neutralizing. Highly specific and rigorously validated in-house, PD-L1 (Atezolizumab Biosimilar) Human Monoclonal Antibody (CST #33052) is ready to ship. Product Usage Information This product is intended for research use only (RUO). Optimal dilutions/concentrations should be determined by the end user. Formulation Supplied in 1X PBS, BSA and Azide Free. Storage Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. Specificity / Sensitivity PD-L1 (Atezolizumab Biosimilar) Human Monoclonal Antibody was confirmed to bind to its intended target protein PD-L1 using flow cytometry and bio-layer interferometry. Species Reactivity: Human Source / Purification PD-L1 (Atezolizumab Biosimilar) Human mAb is produced at Cell Signaling Technology. Atezolizumab is an antibody that is directed against the extracellular region of human PD-L1. Background Programmed cell death 1 ligand 1 (PD-L1, B7-H1, CD274) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. The PD-L1 ligand binds the PD-1 transmembrane receptor and inhibits T cell activation. PD-L1 was discovered following a search for novel B7 protein homologs and was later shown to be expressed by antigen presenting cells, activated T cells, and tissues including placenta, heart, and lung (1-3). Similar in structure to related B7 family members, PD-L1 protein contains extracellular IgV and IgC domains and a short, cytoplasmic region. Research studies demonstrate that PD-L1 is expressed in several tumor types, including melanoma, ovary, colon, lung, breast, and renal cell carcinomas (4-6). Expression of PD-L1 in cancer is associated with tumor-infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma (7). Additional research links PD-L1 expression to cancers associated with viral infections (8,9). Alternate Names B7 homolog 1; B7-H; B7-H1; B7H1; CD274; CD274 antigen; CD274 molecule; hPD-L1; MGC142294; MGC142296; PD-L1; PD1L1; PDCD1 ligand 1; PDCD1L1; PDCD1LG1; PDL1; Programmed cell death 1 ligand 1; Programmed death ligand 1 Specification REACTIVITY: H SENSITIVITY: Endogenous Source/Isotype: Human IgG1 kappa